A comparative study of Cardi-O-Fix septal occluder versus Amplatzer septal occluder in percutaneous closure of secundum atrial septal defects


SARITAŞ T., Kaya M. G. , LAM Y. Y. , ERDEM A., AKDENİZ C., DEMİR F., ...Daha Fazla

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, cilt.82, sa.1, ss.116-121, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 82 Konu: 1
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1002/ccd.23301
  • Dergi Adı: CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
  • Sayfa Sayıları: ss.116-121

Özet

Aim: We sought to investigate the safety and efficacy of Cardio-O-Fix septal occluder (CSO) in percutaneous closure of atrial septal defects (ASD) as compared to the Amplatzer septal occluder (ASO). Methods: A consecutive of 351 patients received transcatheter ASD closure with CSO or ASO from July 2004 to October 2010 were studied. The ASDs were divided into simple- (isolated defects <26 mm) or complex-types (isolated defect 26 mm, double or multifenestrated defects). The procedures were guided by fluoroscopy and transthoracic or transesophageal echocardiography. Clinical and echocardiographic follow-ups were arranged before discharge, at 1 month and then every 6-month after implantation. Results: During the study period, 185 (125 males, aged 18.5 +/- 15.6 years) and 166 (103 males, aged 21.0 +/- 15.7 years) patients attempted CSO and ASO implants, respectively. The CSO group had similar ASD and device sizes, prevalence of complex lesions (17 vs. 16%, P = 0.796), procedural times and success rates (97% vs. 96%, P = 0.635) as compared to the ASO group. Acute residual shunts were less prevalent in CSO than ASO group and most shunts closed spontaneously at 6-month follow-ups. The average equipment cost per patient was lower in CSO group (US$ 4,100 vs. US$ 5,900, P < 0.001). The prevalence of device embolization and atrial arrhythmia (all <2%) were similar in both patient groups. Conclusion: Transcatheter ASD occlusion with CSO is safe and effective and it appeared to be an attractive alternative to ASO in closing simple-type ASD because of its relatively low cost. (c) 2013 Wiley Periodicals, Inc.

Aim: We sought to investigate the safety and efficacy of Cardio-O-Fix septal occluder

(CSO) in percutaneous closure of atrial septal defects (ASD) as compared to the Amplatzer

septal occluder (ASO). Methods: A consecutive of 351 patients received transcatheter

ASD closure with CSO or ASO from July 2004 to October 2010 were studied. The ASDs

were divided into simple- (isolated defects

 

<26 mm) or complex-types (isolated defect 26

mm, double or multifenestrated defects). The procedures were guided by fluoroscopy and

transthoracic or transesophageal echocardiography. Clinical and echocardiographic follow-

ups were arranged before discharge, at 1 month and then every 6-month after implantation.

Results: During the study period, 185 (125 males, aged 18.5

 

6 15.6 years) and 166

(103 males, aged 21.0

 

6 15.7 years) patients attempted CSO and ASO implants, respectively.

The CSO group had similar ASD and device sizes, prevalence of complex lesions (17

vs. 16%,

 

P 5 0.796), procedural times and success rates (97% vs. 96%, P 5 0.635) as compared

to the ASO group. Acute residual shunts were less prevalent in CSO than ASO group

and most shunts closed spontaneously at 6-month follow-ups. The average equipment

cost per patient was lower in CSO group (US$ 4,100 vs. US$ 5,900,

 

P < 0.001). The prevalence

of device embolization and atrial arrhythmia (all

 

<2%) were similar in both patient

groups. Conclusion: Transcatheter ASD occlusion with CSO is safe and effective and it

appeared to be an attractive alternative to ASO in closing simple-type ASD because of its

relatively low cost.